OncoMatch/Clinical Trials/NCT06824467
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Is NCT06824467 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments for ovarian cancer.
Treatment: Sacituzumab tirumotecan · Bevacizumab · H1 receptor antagonist · H2 receptor antagonist · Acetaminophen (or equivalent) · Dexamethasone (or equivalent) · Steroid mouthwash (dexamethasone or equivalent) — The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based doublet chemotherapy — first-line
Has received 4 or more cycles of platinum-based doublet chemotherapy in first-line
Must have received: carboplatin-based doublet chemotherapy (carboplatin) — second-line
a total of 6 to 8 cycles of carboplatin-based doublet chemotherapy in second-line setting for ovarian cancer (OC)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham ( Site 0006) · Birmingham, Alabama
- Alaska Women's Cancer Care ( Site 0096) · Anchorage, Alaska
- UCSF Medical Center at Mission Bay ( Site 0013) · San Francisco, California
- John Muir Health Cancer Center ( Site 0016) · Walnut Creek, California
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001) · New Haven, Connecticut
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06824467 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received platinum-based doublet chemotherapy and carboplatin-based doublet chemotherapy.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages